S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Critical asset just had biggest fall on record (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Is Gold Really Boring? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Critical asset just had biggest fall on record (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Is Gold Really Boring? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Critical asset just had biggest fall on record (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Is Gold Really Boring? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Critical asset just had biggest fall on record (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Is Gold Really Boring? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales

DiaMedica Therapeutics (DMAC) Insider Trading & Ownership

$2.97
+0.13 (+4.58%)
(As of 02/27/2024 ET)

DiaMedica Therapeutics (NASDAQ:DMAC) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
6.50%
Number Of
Insiders Buying
(Last 12 Months)
5
Amount Of
Insider Buying
(Last 12 Months)
$6.24 M
Number Of
Insiders Selling
(Last 12 Months)
0
Get DMAC Insider Trade Alerts

Want to know when executives and insiders are buying or selling DiaMedica Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

DMAC Insider Buying and Selling by Quarter


DiaMedica Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/23/2023David J WambekeInsiderBuy38,364$3.91$150,003.24  
6/23/2023Dietrich John PaulsCEOBuy12,787$3.91$49,997.17  
6/23/2023Koch Thomas VonMajor ShareholderBuy1,470,588$3.40$4,999,999.20  
6/23/2023Randall Michael GiuffreDirectorBuy65,000$3.91$254,150.00  
6/23/2023Scott KellenCFOBuy10,000$3.91$39,100.00  
4/10/2023David J WambekeInsiderBuy468,750$1.60$750,000.00  
(Data available from 1/1/2013 forward)












DMAC Insider Trading Activity - Frequently Asked Questions

Who is on DiaMedica Therapeutics's Insider Roster?

The list of insiders at DiaMedica Therapeutics includes David J Wambeke, Dietrich John Pauls, Harry W Alcorn Jr, Koch Thomas Von, Randall Michael Giuffre, Richard D. Pilnik, and Scott Kellen. Learn more on insiders at DMAC.

What percentage of DiaMedica Therapeutics stock is owned by insiders?

6.50% of DiaMedica Therapeutics stock is owned by insiders. Learn more on DMAC's insider holdings.

Which DiaMedica Therapeutics insiders have been buying company stock?

The following insiders have purchased DMAC shares in the last 24 months: David J Wambeke ($900,003.24), Dietrich John Pauls ($74,197.17), Koch Thomas Von ($5,276,604.62), Randall Michael Giuffre ($362,183.35), and Scott Kellen ($39,100.00).

How much insider buying is happening at DiaMedica Therapeutics?

Insiders have purchased a total of 2,380,021 DMAC shares in the last 24 months for a total of $6,652,088.38 bought.


More Insider Trading Tools from MarketBeat

This page (NASDAQ:DMAC) was last updated on 2/28/2024 by MarketBeat.com Staff